2023-509453-31-00招募中1 期
A phase I study to evaluate the safety and preliminary signs of efficacy of [177Lu]Lu-OncoFAP-23 alone and in combination with L19-IL2 as a treatment of metastatic FAP-positive solid tumors.
Philogen S.p.A.4 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2024年9月18日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 56
- 试验地点
- 4
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Jacqueline Mock
Scientific
Philogen S.p.A.
研究点 (4)
Loading locations...
相似试验
已完成
不适用
A phase I study assessing the safety and performance of VB5-845D-800CW, an anti-Epcam fluorescent agent, for the intraoperative detection of gastrointestinal canceresophageal/gastric- or colorectal cancer10017990NL-OMON48830eids Universitair Medisch Centrum34
进行中（未招募）
1 期
A Safety and Efficacy Study of Nivolumab in Combination with Brentuximab Vedotin to Treat Non-Hodgkin LymphomasEUCTR2015-003286-28-GBBristol-Myers Squibb International Corporation170
进行中（未招募）
1 期
A Safety and Efficacy Study of Nivolumab in Combination with Brentuximab Vedotin to Treat Non-Hodgkin LymphomasEUCTR2015-003286-28-ESBristol-Myers Squibb International Corporation144
进行中（未招募）
不适用
A Safety and Efficacy Study of Nivolumab in Combination with Brentuximab Vedotin to Treat Non-Hodgkin LymphomasEUCTR2015-003286-28-FRBristol-Myers Squibb International Corporation120
进行中（未招募）
1 期
A Safety and Efficacy Study of Nivolumab in Combination with Brentuximab Vedotin to Treat Non-Hodgkin LymphomasRelapsed Refractory Non Hodgkin Lymphomas with CD30 ExpressionMedDRA version: 20.0Level: HLTClassification code 10029606Term: Non-Hodgkin's lymphomas transformed recurrentSystem Organ Class: 100000004851EUCTR2015-003286-28-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO170